Errata: Increased Plasma Soluble Fractalkine in Patients with Chronic Heart Failure and Its Clinical Significance.

Errors appeared in the article entitled "Increased Plasma Soluble Fractalkine in Patients with Chronic Heart Failure and Its Clinical Significance" by Cui-Ling Ji, Adnan Nomi, Bin Li, Cheng Shen, Bing-Chun Song, and Jin-Guo Zhang (Vol. 60, No. 3, 701-707, 2019).

Mesenchymal stem cell-derived extracellular vesicles: a new impetus of promoting angiogenesis in tissue regeneration.

Over the past few decades, extracellular vesicles (EVs) have emerged as crucial mediators of intercellular communication. EVs encapsulate and convey information to surrounding cells or distant cells, where they mediate cellular biological responses. Among their multifaceted roles in the modulation of biological responses, the involvement of EVs in vascular development, growth and maturation has been widely documented and their potential therapeutic application in regenerative medicine or in the treatment of angiogenesis-related diseases is drawing increasing interest.

Increased Plasma Soluble Fractalkine in Patients with Chronic Heart Failure and Its Clinical Significance.

Fractalkine has been reported to play an important role in the pathophysiology of various cardiovascular disorders. This research aims to study the change of soluble fractalkine (sFKN) in plasma level of patients with chronic heart failure (CHF) and evaluate its prognostic value.A total of 96 patients with CHF and 45 healthy subjects were included in this study.